patient

Colorectal Cancer Testing (CRC)

In 2022 the American Cancer Society estimated there would be more than 40,000 new rectal cancer cases and 100,000 new colon cancer cases that year. Colorectal cancer is the third leading cause of cancer deaths for women and men. 

We are committed to helping patients, primary care providers and oncologists screen, diagnose, monitor and manage colorectal cancer. 

For Individuals & Patients

Learn what colorectal cancer is and whether you are at average risk. 

About Colorectal Cancer

For Primary Care Providers

Understand barriers to screening and when fecal-based testing might be appropriate to introduce. 

Screening Barriers & Options

For Oncologists & Pathologists

Explore our complete portfolio of colorectal testing from early screening to treatment and follow-up. 

Colorectal Test Portfolio

Labcorp ColoFITTM- an at home screening test for colorectal cancer

Labcorp ColoFITTM is a fecal immunochemical test (FIT) that is recommended as an early screening detection test for adults over 45 years old who are at average risk.

Labcorp ColoFITTM is a convenient screening option that allows you to collect your sample in the privacy of your home and then send it back to our labs where we look for blood in the stool.

Blood in the stool can have multiple possible causes, so a positive result doesn't mean you have colon cancer. But it does mean your doctor will order a follow-up with additional tests, typically a colonoscopy, to learn more. 

Order a ColoFIT Kit

spanning the continuum of care

A comprehensive colorectal testing portfolio

Our routine and specialty labs offer comprehensive menu of key tests to help screen, diagnose, monitor and manage colorectal cancer.

Screening

  • Labcorp ColoFITTM-fecal occult blood immunoassay

Diagnostic

  • Complex tumor analysis by IHC
  • Comprehensive Lynch syndrome tumor testing

Predictive

  • Various gene mutation analysis for clinical management and decision-making

Monitoring

  • Cancer antigen 19-9
  • Carcinoembryonic antigen (CEA)

Genetic Risk Evaluation

  • VistaSeq® hereditary cancer panels
  • Lynch syndrome germline testing
View the Test Portfolio